JPWO2021237146A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021237146A5
JPWO2021237146A5 JP2022570478A JP2022570478A JPWO2021237146A5 JP WO2021237146 A5 JPWO2021237146 A5 JP WO2021237146A5 JP 2022570478 A JP2022570478 A JP 2022570478A JP 2022570478 A JP2022570478 A JP 2022570478A JP WO2021237146 A5 JPWO2021237146 A5 JP WO2021237146A5
Authority
JP
Japan
Prior art keywords
composition
day
salt
25hc3s
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526418A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033746 external-priority patent/WO2021237146A1/en
Publication of JP2023526418A publication Critical patent/JP2023526418A/ja
Publication of JPWO2021237146A5 publication Critical patent/JPWO2021237146A5/ja
Pending legal-status Critical Current

Links

JP2022570478A 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎(nash)の処置 Pending JP2023526418A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029364P 2020-05-22 2020-05-22
US63/029,364 2020-05-22
US202063030213P 2020-05-26 2020-05-26
US63/030,213 2020-05-26
US202063113119P 2020-11-12 2020-11-12
US63/113,119 2020-11-12
US202163146556P 2021-02-05 2021-02-05
US63/146,556 2021-02-05
PCT/US2021/033746 WO2021237146A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (2)

Publication Number Publication Date
JP2023526418A JP2023526418A (ja) 2023-06-21
JPWO2021237146A5 true JPWO2021237146A5 (enExample) 2024-05-28

Family

ID=78707648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570478A Pending JP2023526418A (ja) 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎(nash)の処置

Country Status (11)

Country Link
US (1) US20230181602A1 (enExample)
EP (1) EP4153165A4 (enExample)
JP (1) JP2023526418A (enExample)
KR (1) KR20230015940A (enExample)
CN (1) CN115803061A (enExample)
AU (1) AU2021273937A1 (enExample)
BR (1) BR112022023128A2 (enExample)
CA (1) CA3183119A1 (enExample)
MX (1) MX2022014574A (enExample)
TW (1) TW202210082A (enExample)
WO (1) WO2021237146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026781A1 (en) 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN105592846A (zh) * 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
KR102462275B1 (ko) * 2016-08-02 2022-11-01 듀렉트 코퍼레이션 산소화 콜레스테롤 술페이트, 및 폴리알킬렌 글리콜, 카르복시메틸 셀룰로오스 및 폴리옥실글리세리드 중 적어도 하나를 포함하는 조성물
MX2019012535A (es) * 2017-04-18 2020-08-17 Genfit Combinacion que comprende un agonista de ppar tal como elafibranor y un inhibidor de la acetil-coa carboxilasa (acc).
JP7479278B2 (ja) * 2017-10-06 2024-05-08 ギリアード サイエンシーズ, インコーポレイテッド Acc阻害剤を含む併用療法

Similar Documents

Publication Publication Date Title
KR101465717B1 (ko) 심혈관 이벤트 발병 예방용 조성물
KR20080070089A (ko) 콜레스테롤 흡수 억제제, HMG-CoA 리덕타제 억제제및 안정화제를 포함하는 조성물
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
EP0904082A1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
CN1330544A (zh) 色伐他丁与贝特的组合
CA2456732A1 (en) Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
IL274414B2 (en) Oral rifamycin sv compositions
JP2009515816A (ja) フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
US20140314844A1 (en) Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability
US20050187204A1 (en) Medicinal composition for lowering blood lipid level
JPWO2021237146A5 (enExample)
US20060188529A1 (en) Stable compositions of fenofibrate with fatty acid esters
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
TWI302457B (en) A pharmaceutical composition for improving blood lipid or reducing blood homocysteine
JPWO2021237143A5 (enExample)
WO2020028124A1 (en) NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS
KR100725263B1 (ko) HMG-CoA 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제
JPWO2022177428A5 (enExample)
Sodipo et al. Drug therapy for hyperlipidaemia (dyslipidaemia)-A review
KR101830977B1 (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
Efthimiadis et al. 2. P. 30 Effect of fluvastatin on coagulant-fibrinolytic system in patients with coronary artery disease
KR101954568B1 (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
CN101897967A (zh) 一种治疗血脂异常的沙棘黄酮复方制剂
KR20130003501A (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
HK1080384B (en) Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent